Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2019 3
2020 9
2021 6
2022 8
2023 2
2024 3
2025 10
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review.
Veraart JKE, Schimmers N, Breeksema JJ, Seybert C, Kamphuis J, Huber LFT, Rota A, Coerts DT, Oliveira-Maia AJ, Schoevers RA. Veraart JKE, et al. Among authors: schoevers ra. Clin Psychol Rev. 2026 Feb 2;124:102706. doi: 10.1016/j.cpr.2026.102706. Online ahead of print. Clin Psychol Rev. 2026. PMID: 41650725 Review.
INTRODUCTION: Ketamine-assisted psychotherapy (KAP) is considered a promising treatment strategy in psychiatric disorders, combining psychotherapeutic interventions with the rapid-acting pharmacological effects of ketamine towards enhancing outcomes. ...Only two stu …
INTRODUCTION: Ketamine-assisted psychotherapy (KAP) is considered a promising treatment strategy in psychiatric disorders, combining …
ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine.
Oude Nijhuis J, Coerts D, van Dalfsen J, Smith-Apeldoorn S, Veraart J, Schoevers R, Touw DJ, van Schaik R. Oude Nijhuis J, et al. Among authors: schoevers r. Pharmacogenomics. 2026 Jan 20:1-7. doi: 10.1080/14622416.2026.2617376. Online ahead of print. Pharmacogenomics. 2026. PMID: 41560413
Oral esketamine is a promising new therapy for treatment-resistant depression. However, concerns exist about interindividual pharmacokinetic variability. ...Utilizing blood samples from a placebo-controlled trial investigating repeated, low dose oral esketamine (N = …
Oral esketamine is a promising new therapy for treatment-resistant depression. However, concerns exist about interindividual pharmaco …
Single fixed-dose intranasal racemic ketamine treatment for the treatment of acute suicidality in a transdiagnostic patient population: Results of a pilot study.
Roelandt GHJ, Strous JFM, Marijnissen RM, Kamphuis J, van Dalfsen JH, Schoevers RA. Roelandt GHJ, et al. Among authors: schoevers ra. Psychiatry Res. 2026 Mar;357:116909. doi: 10.1016/j.psychres.2025.116909. Epub 2025 Dec 16. Psychiatry Res. 2026. PMID: 41456567 Free article. Clinical Trial.
AIMS: Ketamine has been shown to decrease suicidality in patients with depression. However, little is known about tolerability and efficacy in heterogenous, acutely suicidal patients in emergency settings. ...Intranasal ketamine reduced acute suicidality in some cas …
AIMS: Ketamine has been shown to decrease suicidality in patients with depression. However, little is known about tolerability and ef …
The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double-Blind Randomized Placebo-Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality.
Strous JFM, Roelandt GHJ, van Dalfsen JH, Kamphuis J, Marijnissen RM, Schoevers RA. Strous JFM, et al. Among authors: schoevers ra. Int J Methods Psychiatr Res. 2025 Dec;34(4):e70044. doi: 10.1002/mpr.70044. Int J Methods Psychiatr Res. 2025. PMID: 41255293 Free PMC article.
BACKGROUND: Suicidality is a transdiagnostic entity in patients with and without psychiatric disorders. Ketamine is a novel treatment for treatment-resistant depression with favorable effects on related suicidality in this population. Little is known about the effects of …
BACKGROUND: Suicidality is a transdiagnostic entity in patients with and without psychiatric disorders. Ketamine is a novel treatment …
The Association between Intranasal Esketamine and Treatment-emergent Insomnia in the Treatment of Treatment-resistant Major Depression: A Meta-analysis.
Türkmen C, Boesjes R, Zandbergen AF, Kamphuis J, Viechtbauer W, Schoevers RA, van Dalfsen JH. Türkmen C, et al. Among authors: schoevers ra. Clin Psychopharmacol Neurosci. 2025 Aug 31;23(3):494-499. doi: 10.9758/cpn.25.1271. Epub 2025 Apr 8. Clin Psychopharmacol Neurosci. 2025. PMID: 40660695 Free PMC article.
IN esketamine treatment might similarly reduce the incidence of insomnia as an adverse event (AE). ...A mixed-effects logistic regression model was employed to compare the incidence of insomnia as an AE between the IN esketamine and placebo group. RESULTS: Insomnia …
IN esketamine treatment might similarly reduce the incidence of insomnia as an adverse event (AE). ...A mixed-effects logistic regres …
Post-traumatic stress disorder in psychedelic research.
Bostoen T, Tap S, Breeksema J, Schoevers R. Bostoen T, et al. Among authors: schoevers r. Int Rev Neurobiol. 2025;181:329-355. doi: 10.1016/bs.irn.2025.02.004. Epub 2025 Jun 12. Int Rev Neurobiol. 2025. PMID: 40541315 Review.
Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study.
Veraart JKE, Vos CF, Punt NC, Visser D, Wessels MA, Smith-Apeldoorn SY, Kamphuis J, Schoevers RA, Touw DJ. Veraart JKE, et al. Among authors: schoevers ra. Pharmaceuticals (Basel). 2025 Apr 25;18(5):627. doi: 10.3390/ph18050627. Pharmaceuticals (Basel). 2025. PMID: 40430448 Free PMC article.
Background: Esketamine is a rapidly acting antidepressant with robust efficacy in treatment-resistant depression (TRD). ...Methods: Pharmacokinetic data were collected from 18 patients receiving oral esketamine for six weeks. A pharmacokinetic model was developed to …
Background: Esketamine is a rapidly acting antidepressant with robust efficacy in treatment-resistant depression (TRD). ...Methods: P …
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.
Veraart JK, Smith-Apeldoorn SY, van der Meij A, Spijker J, Schoevers RA, Kamphuis J. Veraart JK, et al. Among authors: schoevers ra. J Psychopharmacol. 2025 Jun;39(6):559-570. doi: 10.1177/02698811251332831. Epub 2025 Apr 25. J Psychopharmacol. 2025. PMID: 40285334 Free PMC article.
CONCLUSIONS: Repeated treatment with oral esketamine is effective in improving depressive symptom severity in highly treatment-resistant depressive patients. ...Considering the level of treatment resistance, outcomes were in the range of studies investigating other routes …
CONCLUSIONS: Repeated treatment with oral esketamine is effective in improving depressive symptom severity in highly treatment-resist …
Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.
Veraart JKE, Smith-Apeldoorn SY, Kamphuis J, Touw DJ, Schoevers RA. Veraart JKE, et al. Among authors: schoevers ra. Eur J Pharmacol. 2025 Jul 5;998:177470. doi: 10.1016/j.ejphar.2025.177470. Epub 2025 Mar 7. Eur J Pharmacol. 2025. PMID: 40058750 Free article.
METHODS: Oral esketamine was administered twice weekly for six weeks using a titration approach in 17 patients. Esketamine and noresketamine serum levels were measured 30 min and 60 min after esketamine administration. ...
METHODS: Oral esketamine was administered twice weekly for six weeks using a titration approach in 17 patients. Esketamine and …
Oral Esketamine as Alternative for Maintenance Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Case Series.
Coerts DT, Veraart JKE, Kamphuis J, Smith-Apeldoorn SY, Schoevers RA, van Belkum SM. Coerts DT, et al. Among authors: schoevers ra. J ECT. 2025 Dec 1;41(4):238-243. doi: 10.1097/YCT.0000000000001103. Epub 2025 Jan 21. J ECT. 2025. PMID: 39853300
METHODS: In a 6-week dosing phase, esketamine was titrated from 0.5 or 1.0 mg/kg to a maximum of 3.0 mg/kg twice weekly. Outcomes included 6-week change in Inventory of Depressive Symptomatology - Self-rated (IDS-SR), Hamilton Depression Rating Scale - 17 items (HDRS 17 ), …
METHODS: In a 6-week dosing phase, esketamine was titrated from 0.5 or 1.0 mg/kg to a maximum of 3.0 mg/kg twice weekly. Outcomes inc …
43 results